| 包装: | 1mg |
| 市场价: | 4886元 |
| Canonical SMILES | CC1=C[C@]2([H])[C@@](C(C)(C)OC3=C2C(O)=CC(CC([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=C3)([H])CC1 |
| 分子式 | C21H21D9O2 |
| 分子量 | 323.5 |
| 储存条件 | -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | δ9-THC-d9(CRM) is intended for use as an internal standard for the quantification of δ9-THC-d9by GC- or LC-MS. δ9-THC-d9is categorized as a cannabinoid.1,2It is psychoactive and has diverse effects on perception, cognition, and pain sensitivity.3δ9-THC-d9is regulated as a Schedule I compound in the United States. δ9-THC-d9(CRM) is provided as a DEA exempt preparation. This product is intended for research and forensic applications. 1.Huffman, J.W., Padgett, L.W., Isherwood, M.L., et al.1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: New high affinity ligands for the cannabinoid CB1 and CB2 receptorsBioorg. Med. Chem. Lett.16(20)5432-5435(2006) 2.Pertwee, R.G.Pharmacology of cannabinoid receptor ligandsCurr. Med. Chem.6(8)635-664(1999) 3.Grotenhermen, F.Pharmacokinetics and pharmacodynamics of cannabinoidsClin. Pharmacokinet.42(4)327-360(2003) |
m.cnreagent.com